Abstract:
:We have sought the presence of rearrangements of the immunoglobulin heavy chain gene locus in 13 patients with chronic myeloid leukemia (CML) in lymphoid blastic transformation (L-BT) using the polymerase chain reaction (PCR). The lymphoid nature of the transformation was confirmed by immunophenotyping and/or Southern blot hybridization with a J(H) probe. Clonal rearrangements were detected in 85% of cases and two or more rearrangements were visible in 64% of informative cases. The pattern of V(H) gene family utilization revealed an apparent reduction in V(H)4 family gene usage but otherwise reflected the known proportion of each gene family in the germline repertoire. In six cases the third complementary determining regions (CDR3) of the predominant blast crisis clone/s were sequenced revealing minimal evidence of somatic mutation. No clonal changes were detected in the chronic phase leukemia cells collected more than 6 months before the onset of L-BT in three of these patients. Of the other three patients studied in chronic phase from 1 to 6 months before L-BT, two showed clonal rearrangements which differed in size from those present at L-BT. In one patient a V(H)3 to V(H)5-D(H)-J(H) substitution had occurred at least 3 months prior to L-BT. In the other patient, however, the sequence of the rearrangement present 5 months prior to L-BT was unrelated to the rearrangements at the time of L-BT indicating a pattern of clonal succession. We conclude that: (1) IgH gene rearrangements are detectable in the majority of patients with L-BT using PCR and the lymphoid lineage of blastic CML is most readily confirmed using consensus primers to the framework 3 region; (2) somatic mutation is uncommon; and (3) B lymphoid clones distinct from those identified later may be detected before overt lymphoid BT. The identification of such 'abortive' clones is evidence for clonal instability before the onset of transformation and might have prognostic value.
journal_name
Leukemiajournal_title
Leukemiaauthors
Spencer A,Vulliamy T,Kaeda J,Goldman JM,Melo JVdoi
10.1038/sj.leu.2400543subject
Has Abstractpub_date
1997-02-01 00:00:00pages
195-201issue
2eissn
0887-6924issn
1476-5551journal_volume
11pub_type
杂志文章相关文献
LEUKEMIA文献大全abstract::We used a modification of the polymerase chain reaction (PCR) to amplify the specific bcr-abl mRNA from 14 patients with chronic myeloid leukemia (CML) who had previously received non T cell depleted allogenic bone marrow transplantation (BMT). Two types of reactions were used: a single step amplification with 5' and ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-01-01 00:00:00
abstract::The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic s...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404057
更新日期:2006-02-01 00:00:00
abstract::Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-019-0550-5
更新日期:2019-11-01 00:00:00
abstract::Malignant cells of patients with cutaneous T cell lymphoma (CTCL) are of monoclonal origin and of the CD4+/CD45RO+ subset. Since unlike their normal counterparts, triggering of their TCR/CD3 in vitro elicits only a weak mitogenic response, we set out to determine which of the signal transduction molecules initiated by...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400745
更新日期:1997-08-01 00:00:00
abstract::The immune response to leukemia is poorly understood. We postulated that nonmalignant T lymphocytes remaining within bone marrow from children with newly diagnosed ALL could be involved in this immune response. T lymphocytes which expressed gamma delta TCR comprised less than 1% of ALL marrow cells. A preferential out...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-05-01 00:00:00
abstract::Germline CD95 (also known as FAS, APT1 and APO1) gene mutations have been associated with benign lymphoproliferative diseases and autoimmune processes. Somatic mutations have been reported in human tumours, including lymphomas. Since marginal zone B cell lymphomas usually arise in a background of chronic inflammation,...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401708
更新日期:2000-03-01 00:00:00
abstract::The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0144-7
更新日期:2018-11-01 00:00:00
abstract::Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes. To identify novel imatinib-sensitive lesions, we screened 11 BCR-ABL-neg...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2008.295
更新日期:2009-02-01 00:00:00
abstract::The CEM-ON malignant T cell line and long-term cultured normal T cells can be induced to release CSF-1 in their culture supernatants. Chemical inducers (PMA + A23187) and, more interestingly, cytokines (tumor necrosis factor alpha (TNF alpha) and interleukin-1 alpha (IL-1 alpha)), as well as physiological (antigen + I...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-06-01 00:00:00
abstract::Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). BCR-ABL tyrosine kinase domain (TKD) mutations are associated with acquired imatinib resistance, but their role in primary resistance is uncertain. Using highly sensitive ligat...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2012.5
更新日期:2012-07-01 00:00:00
abstract::Reciprocal rearrangements of the MLL gene are among the most common chromosomal abnormalities in both Acute Lymphoblastic and Myeloid Leukemia. The MLL gene, located on the 11q23 chromosomal band, is involved in more than 40 recurrent translocations. In the present study, we describe the development and validation of ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403439
更新日期:2004-09-01 00:00:00
abstract::Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1038/leu.2010.205
更新日期:2010-12-01 00:00:00
abstract::Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemi...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403861
更新日期:2005-09-01 00:00:00
abstract::Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagno...
journal_title:Leukemia
pub_type: 杂志文章,多中心研究
doi:10.1038/s41375-019-0472-2
更新日期:2019-11-01 00:00:00
abstract::Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun to provide direct...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-019-0703-6
更新日期:2020-03-01 00:00:00
abstract::Only two classes of chemotherapeutic agents have shown activity in acute myeloid leukemia (AML): ara-C and topoisomerase II reactive agents. Frontline combinations of these agents produce complete response (CR) rates of 70% and long-term event free survival rates of 25%. New agents with different mechanisms of action ...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:
更新日期:1996-04-01 00:00:00
abstract::We looked for bcl-2 protein expression by immunocytochemistry on bone marrow slides from 51 cases of myelodysplastic syndrome (MDS), of whom 25 received some form of chemotherapy. Forty-six of them had at least 20% bcl-2 positive blasts and the median percentage of positive blasts was 80%, whereas myeloid cells beyond...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-04-01 00:00:00
abstract::Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity can lead to human diseases including developmental disorders and cancer. Through...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-020-1001-z
更新日期:2020-08-06 00:00:00
abstract::The Bcr/Abl tyrosine kinase that is expressed from the Philadelphia chromosome protects leukemia cells from apoptosis caused by removal of growth factors or by cytotoxic agents and ionizing irradiation. This resistance to apoptosis is associated with a Bcr/Abl-mediated G2/M delay. Therefore, inhibiting Bcr/Abl signali...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401536
更新日期:1999-10-01 00:00:00
abstract::The cell line described here was established for a 50-year-old male patient with rapidly progressive non-Hodgkin's lymphoma whose marrow was diffusely infiltrated with large granular lymphocytes (LGL). Immunophenotyping of marrow blasts and peripheral lymphocytes was positive for CD56, CD2 and CD7, and negative for CD...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-04-01 00:00:00
abstract::A new factor-independent megakaryoblastic cell line, designated SET-2, was established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). SET-2 expressed CD 4, 7, 13, 33, 34, 36, 38, 41, 61, 71, 117, 126, 130 and c-mpl. In addition, it spontaneously produced numerous...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401608
更新日期:2000-01-01 00:00:00
abstract::Polymerase chain reaction (PCR) techniques utilizing clonospecific T cell receptor (TCR) gamma or delta junctional regions constitute broadly applicable strategies to study the clinical relevance of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients. For the majority of cases current PCR pro...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:
更新日期:1995-02-01 00:00:00
abstract::Epidemiological studies have demonstrated an increased leukemia incidence following ionizing radiation exposure, but to date, the target cells and underlying mechanisms of radiation leukemogenesis remain largely unidentified. We engineered a mouse model carrying a different fluorescent marker on each chromosome 2, loc...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0085-1
更新日期:2018-06-01 00:00:00
abstract::We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years fol...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2011.29
更新日期:2011-06-01 00:00:00
abstract::Mutations of the GATA1 gene on chromosome X have been found in almost all cases of transient myeloproliferative disorder and acute megakaryoblastic leukemia (AMKL) accompanying Down syndrome (DS). Although most GATA1 mutations lead to the expression of GATA1s lacking the N-terminal activation domain, we recently found...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404223
更新日期:2006-06-01 00:00:00
abstract::Early in mammalian development, the stem cell leukemia (SCL/TAL1) gene and its distinct 3' enhancer (SCL 3'En) specify bipotential progenitor cells that give rise to blood and endothelium, thus termed hemangioblasts. We have previously detected a minor population of SCL (+) cells in the postnatal kidney. Here, we demo...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404941
更新日期:2008-01-01 00:00:00
abstract::B-cell acute lymphoblastic leukemia (B-ALL) is often associated with chromosomal translocations leading to the deregulation of proto-oncogenes. MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis. The microRNA, miR-125b-1, is overexpressed in B-ALL cases with the t(11;14)(q2...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2012.95
更新日期:2012-10-01 00:00:00
abstract::De novo acute myeloid leukemia (AML) with dysplastic features in erythroblasts, granulocytes and megakaryocytes, similar to those in myelodysplastic syndrome (MDS) has been described as AML with trilineage dysplasia (AML-TLD) since 1987. Several reports have suggested that AML-TLD is a subtype of de novo AML in adults...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401924
更新日期:2000-11-01 00:00:00
abstract::p53 is frequently wild type (wt) in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a is a small molecule that activates the p53 pathway by disrupting p53-MDM2 interaction. We show that nutlin-3a activates p53 in DLBCL cells associated with t(14;18)(q32;q21), BC...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2011.28
更新日期:2011-05-01 00:00:00
abstract::In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402780
更新日期:2003-01-01 00:00:00